文献速递湿疹皮炎与荨麻疹

丝聚蛋白相关湿疹和哮喘个体长期用药和住院费用增加

Individuals with filaggrin-related eczema and asthma have increased long-term medication and hospital admission costs.
PubMed 文献 · Br J Dermatol · 2018-05-31

该研究基于BREATHE横断面数据(苏格兰泰赛德和法夫,2003-2005年,1100例哮喘参与者),链接社区处方与住院记录进行二次分析。发现FLG突变与轻中度湿疹、哮喘缓解药及急性发作的处方增加相关,与润肤剂、重度湿疹治疗及长效β2受体激动剂联合糖皮质激素的处方存在强关联;结论认为需随机对照试验验证针对性管理能否降低疾病负担与费用。

要点

  • FLG突变与湿疹和哮喘的长期处方增加相关。
  • 润肤剂IRR 2.19(95%CI 1.36-3.52),重度湿疹治疗IRR 2.18(95%CI 1.22-3.91)。
  • 长效β2受体激动剂联合激素IRR 3.29(95%CI 1.68-6.43)。

核心结论

  • 在该队列中,FLG突变与湿疹和哮喘的处方增加相关。
  • 需要随机对照试验来确定这些个体是否能从降低疾病负担和治疗费用的管理策略中获益。

研究设计与样本

  • BREATHE研究的二次分析,该研究为基因-环境与哮喘严重程度关联的横断面研究。
  • 数据收集于2003-2005年苏格兰泰赛德和法夫的1100例哮喘参与者。
  • 通过邓迪健康信息中心将BREATHE数据与急诊、社区处方和苏格兰发病率记录链接,进行纵向分析。

主要发现

  • FLG突变与轻度和中度湿疹、哮喘缓解药及哮喘急性发作的处方增加相关。
  • FLG突变与润肤剂处方的关联:IRR 2.19(95%CI 1.36-3.52)。
  • FLG突变与重度湿疹治疗处方的关联:IRR 2.18(95%CI 1.22-3.91)。
  • FLG突变与长效β2受体激动剂联合糖皮质激素处方的关联:IRR 3.29(95%CI 1.68-6.43)。

关键数值与推荐

  • FLG突变与润肤剂处方:IRR 2.19(95%CI 1.36-3.52)。
  • FLG突变与重度湿疹治疗处方:IRR 2.18(95%CI 1.22-3.91)。
  • FLG突变与长效β2受体激动剂联合糖皮质激素处方:IRR 3.29(95%CI 1.68-6.43)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Eczema and asthma are chronic diseases with onset usually before the age of 5 years. More than 50% of individuals with eczema will develop asthma and/or other allergic diseases. Several loss-of-function mutations in filaggrin (FLG) have been identified in patients with eczema. However, the association of FLG with healthcare use is unknown. OBJECTIVES: To determine whether FLG mutations are associated with increased prescribing for eczema and asthma and whether increased prescribing is associated with increased healthcare costs. METHODS: A secondary analysis of BREATHE, a cross-sectional study of gene-environment associations with asthma severity, was undertaken. BREATHE data was collected for 1100 participants with asthma, in Tayside and Fife, Scotland during the period 2003-2005. Through collaboration with the Health Informatics Centre in Dundee, BREATHE was linked to accident and emergency, community prescribing and Scottish morbidity records. The data linkage allowed longitudinal exploration of associations between genetic variation and prescribing. RESULTS: An association was found between FLG mutations and increased prescribing for mild and moderate eczema, asthma-reliever medicine and asthma exacerbations. A strong association was found between FLG mutations and prescribing of emollients [incidence rate ratio (IRR) 2·19, 95% confidence interval (CI) 1·36-3·52], treatment for severe eczema (IRR 2·18, 95% CI 1·22-3·91) and a combination of a long-acting β2 -agonist and corticosteroids (IRR 3·29, 95% CI 1·68-6·43). CONCLUSIONS: The presence of FLG mutations in this cohort is associated with increased prescribing for eczema and asthma. Randomized controlled trials are required to determine if these individuals could benefit from management strategies to reduce morbidity and treatment costs.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Soares P, Fidler K, Felton J, et al. Individuals with filaggrin-related eczema and asthma have increased long-term medication and hospital admission costs. Br J Dermatol. 2018. PMID: 29851030. doi:10.1111/bjd.16720

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。